Prognostic Value of MicroRNA-182 in Cancers: A Meta-Analysis

Objective. MicroRNA-182 (miR-182) exhibits altered expression in various cancers. The aim of this study was to investigate the predictive value of miR-182 expression for cancer patient survival.Methods. Eligible studies were identified through multiple search strategies, and the hazard ratios (HRs) for patient outcomes were extracted and estimated. A meta-analysis was performed to evaluate the prognostic value of miR-182.Results. In total, 14 studies were included. A high miR-182 expression level predicted a worse outcome with a pooled HR of 2.18 (95% CI: 1.53–3.11) in ten studies related to overall survival (OS), especially in Chinese populations. The results of seven studies evaluating disease-free survival/relapse-free survival/recurrence-free interval/disease-specific survival (DFS/RFS/RFI/DSS) produced a pooled HR of 1.77 (95% CI: 0.91–3.43), which was not statistically significant; however, the trend was positive. When disregarding the DSS from one study, the expression of miR-182 was significantly correlated with DFS/RFS/RFI (pooled HR = 2.52, 95% CI: 1.67–3.79).Conclusions. High miR-182 expression is associated with poor OS and DFS/RFS/RFI in some types of cancers, and miR-182 may be a useful prognostic biomarker for predicting cancer prognosis. However, given the current insufficient relevant data, further clinical studies are needed.

Download Full-text

Predictive Prognostic Value of Tissue-Based MicroRNA Expression in Oral Squamous Cell Carcinoma: A Systematic Review and Meta-analysis

Journal of Dental Research ◽

10.1177/0022034518762090 ◽

2018 ◽

Vol 97 (7) ◽

pp. 759-766 ◽

Cited By ~ 27

Author(s):

G. Troiano ◽

F. Mastrangelo ◽

V.C.A. Caponio ◽

L. Laino ◽

N. Cirillo ◽

...

Keyword(s):

Systematic Review ◽

Overall Survival ◽

Squamous Cell Carcinoma ◽

Oral Squamous Cell Carcinoma ◽

Mirna Expression ◽

Prognostic Value ◽

Meta Analysis ◽

Disease Free Survival ◽

Free Survival ◽

Disease Free

Oral squamous cell carcinoma (OSCC) is a common type of cancer characterized by a low survival rate, mostly due to local recurrence and metastasis. In view of the importance of predicting tumor behavior in the choice of treatment strategies for OSCC, several studies have attempted to investigate the prognostic value of tissue biomarkers, including microRNA (miRNA). The purpose of this study was to perform a systematic review and meta-analysis to evaluate the relationship between miRNA expression and survival of OSCC patients. Studies were identified by searching on MEDLINE/PubMed, SCOPUS, Web of Science, and Google Scholar. Quality assessment of studies was performed with the Newcastle-Ottawa Scale. Data were collected from cohort studies comparing disease-free survival and overall survival in patients with high miRNA expression compared to those with low expression. A total of 15 studies featuring 1,200 OSCC samples, predominantly from Asia, met the inclusion criteria and were included in the meta-analysis. Poor prognosis correlated with upregulation of 9 miRNAs (miR-21, miR-455-5p, miiR-155-5p, miR-372, miR-373, miR-29b, miR-1246, miR-196a, and miR-181) and downregulation of 7 miRNAs (miR-204, miR-101, miR-32, miR-20a, miR-16, miR-17, and miR-125b). The pooled hazard ratio values (95% confidence interval) related to different miRNA expression for overall survival and disease-free survival were 2.65 (2.07–3.39) and 1.95 (1.28–2.98), respectively. The results of this meta-analysis revealed that the expression levels of specific miRNAs can robustly predict prognosis of OSCC patients.

Download Full-text

Prognostic value of the C-reactive protein to albumin ratio in colorectal cancer: an updated systematic review and meta-analysis

World Journal of Surgical Oncology ◽

10.1186/s12957-021-02253-y ◽

2021 ◽

Vol 19 (1) ◽

Author(s):

Chun-Kai Liao ◽

Yen-Lin Yu ◽

Yueh-Chen Lin ◽

Yu-Jen Hsu ◽

Yih-Jong Chern ◽

...

Keyword(s):

Colorectal Cancer ◽

Overall Survival ◽

Prognostic Value ◽

Meta Analysis ◽

Disease Free Survival ◽

Progression Free Survival ◽

Poor Overall Survival ◽

Free Survival ◽

Pre Treatment ◽

Disease Free

Abstract Backgrounds The inflammatory biomarker “C-reactive protein to albumin ratio (CAR)” has been reported to significantly correlate to a variety of human cancers. However, there are conflicting results regarding the prognostic value of CAR in colorectal cancer. Previous studies mainly assessed patients in Eastern countries, so their findings may not be applicable to the Western population. Therefore, this updated meta-analysis aimed to investigate the prognostic value of pre-treatment CAR and outcomes of patients with colorectal cancer. Methods We conducted a systematic search for eligible literature until October 31, 2020, using PubMed and Embase databases. Studies assessing pre-treatment CAR and outcomes of colorectal cancer were included. Outcome measures included overall survival, disease-free survival, progression-free survival, and clinicopathological features. The pooled hazard ratios (HR) with 95% confidence intervals (CI) were used as effective values. Results A total of 15 studies involving 6329 patients were included in this study. The pooled results indicated that a high pre-treatment CAR was associated with poor overall survival (HR 2.028, 95% CI 1.808−2.275, p < 0.001) and poor disease-free survival/progression-free survival (HR 1.768, 95% CI 1.321–2.365, p < 0.001). Subgroup analysis revealed a constant prognostic value of the pre-treatment CAR despite different study regions, sample size, cancer stage, treatment methods, or the cut-off value used. We also noted a correlation between high pre-treatment CAR and old age, male sex, colon cancer, advanced stage (III/IV), large tumor size, poor differentiation, elevated carcinoembryonic antigen levels, neutrophil-to-lymphocyte ratio, and the modified Glasgow prognostic score. Conclusions High pre-treatment CAR was associated with poor overall survival, disease-free survival, and progression-free survival in colorectal cancer. It can serve as a prognostic marker for colorectal cancer in clinical practice.

Download Full-text

Prognostic Value of Tumor Infiltrating Lymphocytes in Nasopharyngeal Carcinoma Patients: Meta-Analysis

Technology in Cancer Research & Treatment ◽

10.1177/15330338211034265 ◽

2021 ◽

Vol 20 ◽

pp. 153303382110342

Author(s):

Birhanu Aberha Berele ◽

Yuxiang Cai ◽

Guifang Yang

Keyword(s):

Nasopharyngeal Carcinoma ◽

Prognostic Value ◽

Meta Analysis ◽

Disease Free Survival ◽

Tumor Infiltrating Lymphocytes ◽

Cd4 Cells ◽

Free Survival ◽

Registration Number ◽

Infiltrating Lymphocytes ◽

Disease Free

Objective: To evaluate the prognostic value of tumor infiltrating lymphocytes (TILs) in nasopharyngeal carcinoma (NPC) patients. Method: Meta-analysis was performed on eligible studies that was identified by systematic searching of Google scholar, MEDLINE, CNKI, Scopus, PubMed, PMC, Embase and Web of Science databases. The study protocol was registered in International Platform of Registered Systematic Review and Meta-Analysis Protocols-INPLASY (registration number: INPLASY202160014). Databases were searched from inception to January 20, 2020 to identify eligible studies. Those studies that evaluated survival in the form of hazard ratio (HR) in TILs of NPC patients was analyzed. All statistical analysis was performed by using STATA version 16.0 software. Result: Fourteen studies with a total of 3025 patients was analyzed. The pooled result showed that high TILs was significantly associated with favorable overall survival (OS) (HR = 0.55; 95%CI = 0.39-0.77; P = 0.001) and disease free survival (DFS) (HR = 0.60; 95%CI = 0.44-0.81; P = 0.04). Interestingly, high intratumoral TILs had relatively better OS (HR = 0.45; 95%CI = 0.35-0.58; P = 0.006) than stromal TILs (HR = 0.59; 95%CI = 0.36-0.97; P = 0.03). Moreover, an increased level of CD4+ cells infiltration was correlated with favorable OS (HR = 0.4; 95%CI = 0.18-0.85; P = 0.01). CD3+, CD8+ and FoxP3+ lymphocyte’s better prognosis was not statistically significant for OS ( P = 0.09; P = 0.07; P = 0.52) and for DFS ( P = 0.13; P = 0.29) respectively. However, subgroup analysis of intratumoral CD3+ (HR = 0.48; 95%CI = 0.33-0.70; P = 0.05) and intratumoral CD8+ (HR = 0.32; 95%CI = 0.16-0.62; P = 0.001) was significantly associated with improved OS, but not significant in stromal CD3+ (HR = 0.66; 95%CI = 0.20-2.20; P = 0.62). Conclusion: TILs were variably correlated with better prognosis depending on their microanatomic location and subset of TILs in NPC patients. CD4+, intratumoral CD3+ and intratumoral CD8+ lymphocytes could predict favorable patient outcome which suggest that their role in mediating antitumor immune response could potentially be exploited in the treatment of NPC patients. Future large study on the prognostic value of microanatomic location of TILs is needed for confirmation.

Download Full-text

CHI3L1 Expression is a Prognostic Marker for Patients with Diagnosed Solid Tumors: Evidence from a Systematic Review and Meta-Analysis

10.21203/rs.3.rs-26219/v1 ◽

2020 ◽

Author(s):

jianyuan pan ◽

Liping Wu ◽

Shiwu Yin ◽

Yongqin Tang ◽

Jing Zhang ◽

...

Keyword(s):

Solid Tumors ◽

Prognostic Biomarker ◽

Meta Analysis ◽

Disease Free Survival ◽

Tissue Expression ◽

Cancer Prognosis ◽

Current Evidence ◽

Free Survival ◽

Promising Therapeutic Target ◽

Disease Free

Abstract Background: Accumulating studies have demonstrated YKL-40 associated with the prognosis of several cancers and contributed to the tumor progression through promoting tumor angiogenesis, migration, invasion and metastasis. The objective of this meta-analysis was to investigatethe relationship between YKL-40 and prognosis inpatients with solid tumors and seek for a new prognostic biomarker.Method: Relevant studies were searched in the Medline (PubMed), Web of science, and Embase. Pooled HR of overall survival and disease-free survival (DFS) were calculated to evaluate the strengthof the association between YKL-40 and cancer prognosis by using Stata software 14.0.Results: In total, 30 studies comprising 5160 patients were considered eligible and enrolled into the final meta-analysis. According to the meta-analysis results, higher expression of YKL-40 predicted poorer OS (pooled HR=1.85 CI%=1.58-2.18；P<0.001) and DFS (pooled HR =3.63 95% CI =2.63-5.01; P<0.001).Conclusion: The current evidence suggests that YKL-40 has a predictive effect onsurvival of cancer patients as indexed by DFS and OS. YKL-40 tissue expression is a valuable prognostic biomarker and may be a promising therapeutic target for solid tumors.

Download Full-text

The Prognostic Value of lncRNA SNHG3 in Cancer Patients: A meta-analysis

10.21203/rs.3.rs-91124/v1 ◽

2020 ◽

Author(s):

Jie Wang ◽

Pingyong Zhong ◽

Hao Hua

Keyword(s):

Cancer Patients ◽

Prognostic Value ◽

Meta Analysis ◽

Disease Free Survival ◽

Cochrane Library ◽

Multiple Cancer ◽

Free Survival ◽

Node Metastasis ◽

Hazard Ratios ◽

Clinicopathological Significance

Abstract Background:Small nucleolar RNA host gene 3 (SNHG3) is a promising long non-coding RNA that may possess prognostic value for different types of tumors. The objective of this meta-analysis is to evaluate the prognostic value of lncRNA SNHG3 in cancer patients.Methods:A systematic literature search of the PubMed, Cochrane Library, EMBASE, Medline, Web of Science, CNKI, Weipu, and Wanfang electronic databases was carried out in this meta-anaysis. The synthetic hazard ratios (HRs) or odd ratios (ORs) with 95% confidence intervals (CIs) were obtained to determine the prognostic and clinicopathological significance of SNHG3 expression in tumors. Results:The final meta-anaysis included 17 studies that contained 2072 patients. The pooled results provided evidence that SNHG3 overexpression predicted reduced overall survival (OS) (HR=2.15, 95%CI: 1.76–2.63, P<0.00001), recurrence-free survival (RFS) ( HR=2.22, 95%CI: 1.04–4.76, P=0.04) and disease-free survival (DFS) (HR=2.04, 95%CI: 1.35–3.09, P=0.0007) for various cancers. Additionally, the SNHG3 overexpression was concerned with tumor node metastasis (TNM) stage (III/IV vs. I/II, OR=2.91, 95%CI: 1.60–5.29, P=0.0005), lymph node metastasis (LNM) (positive vs negative, OR=5.00,95%CI:2.82–8.87,P＜0.00001), distant metastasis (DM) (positive vs negative, OR=2.29, 95%CI: 1.52–3.47, P<0.0001) and tumor size (larger vs smaller, OR=1.80, 95%CI: 1.04–3.11, P=0.04).Conclusions:Our results indicated that SNHG3 overexpression was closely correlated with shorter OS in multiple cancer types, suggesting that SNHG3 might function as a promising predictor for clinical outcomes in cancer.

Download Full-text

Prognosis Value of Low microRNA-34a Expression in Human Gastrointestinal Cancer: A Meta-Analysis

10.21203/rs.3.rs-63455/v1 ◽

2020 ◽

Author(s):

Yan-Ling Chen ◽

Xiao-Lin Liu ◽

Ling Li

Keyword(s):

Meta Analysis ◽

Disease Free Survival ◽

Clinicopathological Characteristics ◽

Cancer Prognosis ◽

Expression Level ◽

Significant Relation ◽

Free Survival ◽

Predictive Role ◽

Disease Free

Abstract Background: Mounting evidence shows that microRNA-34a (miR-34a) is involved in cancer prognosis. Therefore, we summarize the predictive role of miR-34a for survival in patients with gastrointestinal cancers (GICs). Methods: All the eligible studies were searched by PubMed, Web of Science and EMBASE and survival results were extracted. Then, the hazard ratio (HR) with corresponding 95% confidence intervals (CIs) was calculated to evaluate the prognostic role of miR-34a in GICs. The association between miR-34a expression and clinicopathological characteristics was estimated by odds ratio (OR) and 95%CIs. Results: A total of 20 studies were included in this meta-analysis. For overall survival (OS), the lower miR-34a expression significantly predicted poorer outcome in GICs, with the pooled HR of 1.86 (95% CI: 1.52-2.28, P<0.01). For disease-free survival (DFS), progressive-free survival (PFS), and recurrence-free survival (RFS), the lower miR-34a expression revealed worse DFS/PFS/RFS with the pooled HR of 1.86 (95% CI: 1.31–2.63, P < 0.01). Significant relation of differentiation/TMN stage/lymphatic metastasis and the expression level of miR-34a was identified. Conclusion: This meta-analysis reveals that lower miR-34a expression is significantly connected with worse OS and DFS/PFS/RFS of GICs patients. In addition, miR-34a expression level is relatively lower in patients with lymph node metastasis than patients without, and decreased miR-34a expression level is linked to poor tumor differentiation and late TMN stage. MiR-34a may become a new factor for prognosis prediction and progression of GICs.

Download Full-text

Disease-free survival as a surrogate endpoint for overall survival in an adjuvant trial of curatively resected stomach cancer using individual patient data meta-analysis

Journal of Clinical Oncology ◽

10.1200/jco.2009.27.15_suppl.4517 ◽

2009 ◽

Vol 27 (15_suppl) ◽

pp. 4517-4517

Author(s):

T. Burzykowski ◽

Y. Bang ◽

Keyword(s):

Stomach Cancer ◽

Meta Analysis ◽

Rank Correlation ◽

Disease Free Survival ◽

Resected Stomach ◽

Free Survival ◽

Spearman’S Rank Correlation ◽

Hazard Ratios ◽

Disease Free

4517 Background: In investigations of the effectiveness of oncology drugs, overall survival (OS) is considered as the gold standard end point. However, the disadvantage of OS is that it requires an extended follow-up. A reasonable candidate for a surrogate for OS in the adjuvant setting is disease free survival (DFS). DFS is defined as recurrence of stomach cancer, all second cancers, or death from any cause. Recently, some evidence has been offered for the use of DFS as a surrogate for OS in, e.g., colorectal cancer. We evaluated 3 year DFS as a surrogate for 5 year OS in adjuvant trials of stomach cancer by using individual-patient data (IPD) meta- analysis validation criteria. Methods: The GASTRIC group initiated an IPD meta-analysis of all randomized clinical trials comparing chemotherapy versus surgery alone for patients with curatively resected stomach cancer. The validity of DFS at 3 years as a surrogate for OS at 5 years was investigated by using multiple analysis techniques, which included measures of correlation between the endpoints and between the treatment effects, and the percentage of agreement in the log-rank tests for the two endpoints at the trial level. Results: Among the 31 eligible trials, at most 25 collected the date of recurrence (5,014 pts). As of December 2008, IPD were available from 13 randomized controlled trials (3,161 patients). Seventy-seven percent of patients (1,280/1,652 pts) who recurred during the follow-up period, recurred within the first 3 years after study enrollment. At the trial level, 12 out of the 13 trials yielded the same conclusions for both endpoints at the 0.05 significance level. The R2 value between both endpoints was equal to 0.97 and Spearman's rank correlation was equal to 0.92. The R2 value between hazard ratios for OS and DFS was equal to 0.85 and Spearman's rank correlation was equal to 0.87. Conclusions: Our preliminary results, which are based on 63% of the targeted data, show that the 5-year OS and the 3-year DFS are highly correlated. Additionally, the hazard ratios for DFS and OS are also strongly associated. This suggests that 3-year DFS may be a good surrogate for a 5-year OS. The results based on the most recent update of the IPD will be presented during the conference. No significant financial relationships to disclose.

Download Full-text

The prognostic significance of microRNA-221 in hepatocellular carcinoma: An updated meta-analysis

The International Journal of Biological Markers ◽

10.1177/17246008211032689 ◽

2021 ◽

Vol 36 (2) ◽

pp. 172460082110326

Author(s):

Wenfeng Liu ◽

Keshu Hu ◽

Feng Zhang ◽

Shenxin Lu ◽

Rongxin Chen ◽

...

Keyword(s):

Hepatocellular Carcinoma ◽

Overall Survival ◽

Meta Analysis ◽

Prognostic Significance ◽

Disease Free Survival ◽

Progression Free Survival ◽

Recurrence Free Survival ◽

Free Survival ◽

Hazard Ratios ◽

Disease Free

Background Recently, microRNA-221 has been found to be abnormally expressed in hepatocellular carcinoma; however, its clinical value has not been summarised. This meta-analysis aimed to assess the prognostic significance of miR-221 in hepatocellular carcinoma. Material and Methods PubMed, Science Direct, Web of Science, Scopus, Ovid MEDLINE, EMbase, Google Scholar, the Cochrane Library, CNKI, CBM, VIP and Wanfang databases were searched for eligible articles. The endpoints included overall survival, progression-free survival, recurrence-free survival, metastasis-free survival, disease-free survival. Hazard ratios with 95% confidence intervals were used to explore the relationship between miR-221 expression and clinical survival results of liver cancer patients. Subgroup analysis and sensitivity analysis were performed. Begg’s test and Egger’s test were conducted to evaluate publication bias. Results A total of nine studies including 607 patients were recruited for this meta-analysis. The pooled hazard ratios displayed that high miR-221 expression was remarkably associated with poorer overall survival (hazard ratio = 1.91, 95% confidence interval: 1.53–2.38, p ＜ 0.01) and unfavourable progression-free survival/recurrence-free survival/metastasis-free survival/disease-free survival (hazard ratio = 2.02, 95% confidence interval: 1.58–2.57, p ＜ 0.01). The results of Begg’s test and Egger’s test did not exhibit obvious publication bias. Conclusions High expression of miR-221 can predict poor outcome of hepatocellular carcinoma. miR-221 can be used as a promising prognostic biomarker of hepatocellular carcinoma.

Download Full-text

Prognostic Role of C-Reactive Protein in Breast Cancer: A Systematic Review and Meta-Analysis

The International Journal of Biological Markers ◽

10.5301/jbm.2011.8872 ◽

2011 ◽

Vol 26 (4) ◽

pp. 209-215 ◽

Cited By ~ 53

Author(s):

Yijie Han ◽

Feng Mao ◽

Ying Wu ◽

Xiaonan Fu ◽

Wei Zhang ◽

...

Keyword(s):

Breast Cancer ◽

Meta Analysis ◽

Disease Free Survival ◽

C Reactive Protein ◽

Cancer Specific Survival ◽

Free Survival ◽

Reactive Protein ◽

Hazard Ratios ◽

Disease Free

Background Recent studies have shown that C-reactive protein (CRP) may be associated with breast cancer. The purpose of this study is to summarize the predictive role of CRP for survival in breast cancer as shown in all available studies worldwide. Methods Related studies were identified and evaluated for quality through multiple search strategies. Data were collected from studies comparing overall, cancer-specific, and disease-free survival (OS, CSS, and DFS) in patients with elevated CRP levels and those having lower levels. Studies were pooled, and combined hazard ratios (HRs) of CRP for survival were calculated. Results A total of 10 studies (n=4,502) were included for this meta-analysis (9 for OS, 3 for CSS, and 3 for DFS). For overall and disease-free survival, the pooled HRs of CRP were significant at 1.62 (95% confidence interval [95% CI], 1.20-2.18) and 1.81 (95% CI, 1.44-2.26), respectively. For cancer-specific survival, the pooled HR in higher CRP expression in breast cancer was 2.08 (95% CI, 1.48-2.94), which could strongly predict poorer survival in breast cancer. Conclusions CRP has a critical prognostic value in patients with breast cancer as an inflammation biomarker.

Download Full-text

The Prognostic Value of Decreased KLF4 in Digestive System Cancers: A Meta-Analysis from 17 Studies

Disease Markers ◽

10.1155/2017/3064246 ◽

2017 ◽

Vol 2017 ◽

pp. 1-11

Author(s):

Jianpei Hu ◽

Huipu Li ◽

Chunyu Wu ◽

Xueying Zhao ◽

Chaodong Liu

Keyword(s):

Prognostic Value ◽

Digestive System ◽

Meta Analysis ◽

Disease Free Survival ◽

Free Survival ◽

Hazard Ratios ◽

Klf4 Expression ◽

Prognostic Implications ◽

Esophagus Squamous Cell Carcinoma ◽

Degree Of Association

Background. The prognostic value of loss of Krüppel-like factor 4 (KLF4) expression in digestive system cancers has not reached a consensus. This study aimed for a comprehensive investigation of the internal associations between KLF4 expression loss and prognostic implications in patients with digestive system cancers. Methods. We searched for all relevant literatures in the electronic databases until February 1, 2017. The degree of association between KLF4 and prognosis was evaluated by pooled hazard ratios (HRs) as well as relevant 95% confidence intervals (95% CIs). Results. Seventeen eligible studies with 2118 patients revealed that loss of KLF4 expression was connected with poor prognosis, with the pooled HRs of 1.61 (95% CI: 1.17–2.20, P=0.003) for the overall survival (OS) and 1.99 (95% CI: 1.12–3.52, P=0.001) for the disease-free survival (DFS)/recurrence-free survival (RFS)/metastasis-free survival (MFS). Additionally, loss of KLF4 expression was also related to a worse disease-special survival (DSS) yielding a pooled HR of 1.73 (95% CI: 1.08–2.77, P=0.022). Conclusion. Our findings suggest that loss of KLF4 expression is correlated with a bad outcome in most digestive system cancers, apart from esophagus squamous cell carcinoma (ESCC).

Download Full-text